Search

Displaying results 3201 - 3210 of 4590 in total
  1. Drug

    Flurbiprofen axetil

    go.drugbank.com/drugs/DB14938
    Investigational

    Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

  2. Drug

    LY3884961

    go.drugbank.com/drugs/DB17070
    Investigational

    LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]

  3. Drug

    MBP-091

    go.drugbank.com/drugs/DB17741
    Experimental

    MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]

  4. Drug

    Clofedanol

    go.drugbank.com/drugs/DB04837
    ApprovedWithdrawn

    Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

  5. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%). … [T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.

  6. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors

  7. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012.

  8. Drug

    D-Proline

    go.drugbank.com/drugs/DB02853
    Experimental

    These amino acids may be of bacterial origin, but there is also evidence that they are endogenously produced through amino acid racemase activity [A19263].

  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  10. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)